Heart transplantation in Danon disease: Long term single centre experience and review of the literature

Danon disease is characterized by hypertrophic cardiomyopathy, skeletal myopathy, and intellectual disability due to deficiency of the lysosome-associated membrane protein-2 (LAMP-2). Although heart transplantation is considered an option for end stage Danon cardiomyopathy, scarce information is available about long term follow up. We report on long term follow up (14.7 years, IQ range 9–21 years) of 4 patients, transplanted for Danon disease cardiomyopathy, showing two LAMP-2 gene variants, the novel c.815T > C and the previously reported c.294G > A. We have also analysed previous published paper on this topic comparing available data from different follow up. Being a skeletal and cardiac muscle disease, with systemic effects, long term results about HTx are indispensable to justify any treatments in this subset of patients.     

Skin-resident natural killer T cells participate in cutaneous allergic inflammation in atopic dermatitis

1. Download : Download high-res image (308KB)
2. Download : Download full-size image

     

Unsupervised modeling and genome-wide association identify novel features of allergic march trajectories

1. Download : Download high-res image (257KB)
2. Download : Download full-size image

     

Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review

BackgroundMore and more novel anticancer drugs have been approved for patients with hematological malignancies in recent years, but HBV reactivation (HBV-R) data in this population is very scarce. This study aimed to evaluated HBV-R risk in patients with hematological malignancies receiving novel anticancer drugs.MethodsHBV markers and serum HBV DNA levels of patients with hematological malignancies receiving novel anticancer drugs in a tertiary cancer hospital were retrospectively collected. HBV-R risk in the whole cohort and subgroups was described. The relevant literature was reviewed to make a pooled analysis.ResultsOf 845 patients receiving novel anticancer drugs, 258 (30.5%) were considered at risk for HBV-R. The median duration of exposure to novel drugs was 5.6 (0.1–67.6) months. The incidence of HBV-R was 2.1% in patients with past HBV infection without prophylactic antiviral treatment (PAT) and 1.2% in all patients at risk of HBV-R. In a pooled analysis of 11 studies with 464 patients, the incidence of HBV-R was 2.4% (95% CI: 1.3–4.2) in all at-risk patients receiving novel anticancer drugs and 0.6% (95% CI: 0.03–3.5) in patients with anticancer drugs plus PAT. The incidence of death due to HBV-R was 0.4% (95% CI: 0.1–1.6) in all at-risk patients and 18.2% (95% CI: 3.2–47.7) in patients with HBV-R.ConclusionMost episodes of HBV-R are preventable, and most cases with HBV-R are manageable. We recommend that novel anticancer drugs should not be intentionally avoided when treating cancer patients with HBV infection.     

Microbiome-induced antigen-presenting cell recruitment coordinates skin and lung allergic inflammation

1. Download : Download high-res image (202KB)
2. Download : Download full-size image

     

Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib

1. Download : Download high-res image (225KB)
2. Download : Download full-size image

     

Allergen-induced DNA release by the airway epithelium amplifies type 2 immunity

1. Download : Download high-res image (223KB)
2. Download : Download full-size image

     

Endotypes of chronic rhinosinusitis based on inflammatory and remodeling factors

1. Download : Download high-res image (358KB)
2. Download : Download full-size image

     

Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis

1. Download : Download high-res image (270KB)
2. Download : Download full-size image

     

IL-4–BATF signaling directly modulates IL-9 producing mucosal mast cell (MMC9) function in experimental food allergy

1. Download : Download high-res image (233KB)
2. Download : Download full-size image